<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pediatricjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Архив педиатрии и детской хирургии</journal-title><trans-title-group xml:lang="en"><trans-title>Archives of Pediatrics and Pediatric Surgery</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2949-4664</issn><issn pub-type="epub">3033-6783</issn><publisher><publisher-name>НИКИ детства Минздрава Московской области</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31146/2949-4664-apps-2-1-96-103</article-id><article-id custom-type="elpub" pub-id-type="custom">pediatricjournal-62</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИНФЕКЦИОННЫЕ БОЛЕЗНИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>INFECTIOUS DISEASES</subject></subj-group></article-categories><title-group><article-title>Особенности патогенеза COVID-19 у детей</article-title><trans-title-group xml:lang="en"><trans-title>Immunological aspects of COVID-19 in children</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8212-9251</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Волков</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Volkov</surname><given-names>A. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6945-2019</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Руженцова</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ruzhentsova</surname><given-names>T. A.</given-names></name></name-alternatives><email xlink:type="simple">ruzhencova@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Федеральное бюджетное учреждение науки «Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г. Н. Габричевского» федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека<country>Россия</country></aff><aff xml:lang="en">Gabrichevsky Research Institute for Epidemiology and Microbiology<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Федеральное бюджетное учреждение науки «Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г. Н. Габричевского» федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека; Частное учреждение высшего образования Московский медицинский университет «РЕАВИЗ»<country>Россия</country></aff><aff xml:lang="en">Gabrichevsky Research Institute for Epidemiology and Microbiology; Moscow Medical University “Reaviz”<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>26</day><month>03</month><year>2024</year></pub-date><volume>2</volume><issue>1</issue><fpage>96</fpage><lpage>103</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Волков А.В., Руженцова Т.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Волков А.В., Руженцова Т.А.</copyright-holder><copyright-holder xml:lang="en">Volkov A.V., Ruzhentsova T.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nikid.ru/jour/article/view/62">https://journal.nikid.ru/jour/article/view/62</self-uri><abstract><p>Авторами представлен обзор литературы, посвященной особенностям иммунитета у детей, которые могут быть объяснением отличий симптоматики COVID-19 в детском возрасте. У детей COVID-19, как правило, протекает более легко, чем у взрослых. Однако, как и в годы пандемии, так и в постпандемийный период, отмечено не мало случаев осложненного течения с необходимостью госпитализации, а иногда, - и с летальными исходами. На младенцев в возрасте до 1 года приходится самый высокий процент госпитализаций среди детей. В настоящее время продолжается анализ результатов сопоставления клинических проявлений болезни и данных лабораторных исследований. В основном, особенности COVID-19 у детей объясняются незрелостью иммунной системы и мерцательного эпителия дыхательных путей. Известно, что в детском возрасте имеется меньшее количество рецепторов ангиотензинпревращающего фермента 2 типа (АПФ 2, АСЕ 2), с помощью которых коронавирус проникает в организм человека. Заболевание, вызываемое SARS-CoV-2, у детей часто сопровождается желудочно-кишечными проявлениями. У небольшого процента заболевших детей может развиться интенсивная воспалительная реакция, которая называется «мультисистемный воспалительный синдром», также известный как MIS-C. При этом состоянии обнаруживают высокие титры антител к RBD SARS-CoV-2 и аутоантитела к свободному интерлейкину (IL) -1Ra. Эти данные необходимо учитывать при уточнении схем профилактики и лечения, направленного на предупреждение осложнений, в педиатрической популяции.</p></abstract><trans-abstract xml:lang="en"><p>The authors present a review of the literature on the peculiarities of immunity in children, which may explain the differences in the symptoms of COVID-19 in childhood. In children, COVID-19 tends to occur more easily than in adults. However, as in the years of the pandemic, and in the post-pandemic period, there were quite a few cases of complicated course with the need for hospitalization, and sometimes with fatal outcomes. Infants under the age of 1 year account for the highest percentage of hospitalizations among children. Currently, the analysis of the results of comparing the clinical manifestations of the disease and laboratory data is continuing. Basically, the features of COVID-19 in children are explained by the immaturity of the immune system and the atrial fibrillation of the respiratory tract. It is known that in childhood there are fewer angiotensin converting enzyme type 2 receptors (ACE 2, ACE 2), with which the coronavirus enters the human body. The disease caused by SARS-CoV-2 in children is often accompanied by gastrointestinal manifestations. A small percentage of sick children may develop an intense inflammatory reaction called “multisystem inflammatory syndrome”, also known as MIS-C. In this condition, high titers of antibodies to RBD SARS-CoV-2 and autoantibodies to free interleukin (IL) -1Ra are detected. These data should be taken into account when clarifying the prevention and treatment regimens aimed at preventing complications in the pediatric population.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>дети</kwd><kwd>мультисистемный воспалительный синдром</kwd><kwd>гуморальный иммунитет</kwd><kwd>клеточный иммунитет</kwd></kwd-group><kwd-group xml:lang="en"><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>children</kwd><kwd>multisystem inflammatory syndrome</kwd><kwd>humoral immunity</kwd><kwd>cellular immunity</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Yuki К.,Fujiogi М., Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020; 215: 108427. doi: 10.1016/j.clim.2020.108427</mixed-citation><mixed-citation xml:lang="en">Yuki К.,Fujiogi М., Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020; 215: 108427. doi: 10.1016/j.clim.2020.108427</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Wu Z., McGoogan J. M. Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13): 1239-1242. doi: 10.1001/jama.2020.2648.</mixed-citation><mixed-citation xml:lang="en">Wu Z., McGoogan J. M. Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13): 1239-1242. doi: 10.1001/jama.2020.2648.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Dong Y., Mo X., Hu Y. et al. Epidemiology of COVID-19 Among Children in China. Pediatrics. 2020;145(6): e20200702. doi: 10.1542/peds.2020-0702.</mixed-citation><mixed-citation xml:lang="en">Dong Y., Mo X., Hu Y. et al. Epidemiology of COVID-19 Among Children in China. Pediatrics. 2020;145(6): e20200702. doi: 10.1542/peds.2020-0702.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Livingston E., Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA. 2020; 323(14): 1335. doi: 10.1001/jama.2020.4344.</mixed-citation><mixed-citation xml:lang="en">Livingston E., Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA. 2020; 323(14): 1335. doi: 10.1001/jama.2020.4344.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Furman E. G. Coronavirus infection COVID-19 and children. Pediatria n. a. G. N. Speransky. 2020; 99 (3): 245-251. (In Russ.) doi: 10.24110/0031-403X-2020-99-3-245-251.@@ Фурман Е. Г. Коронавирусная инфекция COVID-19 и дети. Педиатрия им. Г. Н. Сперанского. 2020; 99 (3): 245-251. doi: 10.24110/0031-403X-2020-99-3-245-251.</mixed-citation><mixed-citation xml:lang="en">Furman E. G. Coronavirus infection COVID-19 and children. Pediatria n. a. G. N. Speransky. 2020; 99 (3): 245-251. (In Russ.) doi: 10.24110/0031-403X-2020-99-3-245-251.@@ Фурман Е. Г. Коронавирусная инфекция COVID-19 и дети. Педиатрия им. Г. Н. Сперанского. 2020; 99 (3): 245-251. doi: 10.24110/0031-403X-2020-99-3-245-251.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Valentini B., Sodero G., Buonsenso D. The Relationship between COVID-19 and Innate Immunity in Children: A Review. Children. 2021; 8(4): 266. doi: 10.3390/children8040266.</mixed-citation><mixed-citation xml:lang="en">Valentini B., Sodero G., Buonsenso D. The Relationship between COVID-19 and Innate Immunity in Children: A Review. Children. 2021; 8(4): 266. doi: 10.3390/children8040266.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bitar R. R., Alattas B., Azaz A. et al. Gastrointestinal manifestations in children with COVID-19 infection: Retrospective tertiary center experience. Front Pediatr. 2022; 10: 925520. doi: 10.3389/fped.2022.925520.</mixed-citation><mixed-citation xml:lang="en">Bitar R. R., Alattas B., Azaz A. et al. Gastrointestinal manifestations in children with COVID-19 infection: Retrospective tertiary center experience. Front Pediatr. 2022; 10: 925520. doi: 10.3389/fped.2022.925520.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Gorelov A. V., Nikolaeva S. V., Usenko D. V. et al. The effectiveness of using nifuroxazide in acute intestinal infections of bacterial etiology in children. Infekc. bolezni (Infectious diseases). 2018; 16(2): 18-26. (In Russ.) doi: 10.20953/1729-9225-2018-2-18-26.@@ Горелов А. В., Николаева С. В., Усенко Д. В. и др. Эффективность применения нифуроксазида при острых кишечных инфекциях бактериальной этиологии у детей. Инфекционные болезни. 2018; 16(2): 18-26. doi: 10.20953/1729-9225-2018-2-18-26.</mixed-citation><mixed-citation xml:lang="en">Gorelov A. V., Nikolaeva S. V., Usenko D. V. et al. The effectiveness of using nifuroxazide in acute intestinal infections of bacterial etiology in children. Infekc. bolezni (Infectious diseases). 2018; 16(2): 18-26. (In Russ.) doi: 10.20953/1729-9225-2018-2-18-26.@@ Горелов А. В., Николаева С. В., Усенко Д. В. и др. Эффективность применения нифуроксазида при острых кишечных инфекциях бактериальной этиологии у детей. Инфекционные болезни. 2018; 16(2): 18-26. doi: 10.20953/1729-9225-2018-2-18-26.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ruzhentsova T. A., Ploskireva A. A., Milutina L. N., Gorelov A. V. Features of the use of antibacterial therapy in children with acute intestinal infections. Meditsinskiy Sovet. 2016; 1: 98-101. (In Russ.)@@ Руженцова Т. А., Плоскирева А. А., Милютина Л. Н., Горелов А. В. Особенности применения антибактериальной терапии у детей при острых кишечных инфекциях. Медицинский совет. 2016; 1: 98-101.</mixed-citation><mixed-citation xml:lang="en">Ruzhentsova T. A., Ploskireva A. A., Milutina L. N., Gorelov A. V. Features of the use of antibacterial therapy in children with acute intestinal infections. Meditsinskiy Sovet. 2016; 1: 98-101. (In Russ.)@@ Руженцова Т. А., Плоскирева А. А., Милютина Л. Н., Горелов А. В. Особенности применения антибактериальной терапии у детей при острых кишечных инфекциях. Медицинский совет. 2016; 1: 98-101.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ruzhentsova T. A., Ploskireva A. A., Gorelov A. V. Acute diarrhea of bacterial etiology: differential diagnosis and treatment. Meditsinskiy Sovet. 2016; 7: 78-81. (In Russ.) doi: 10.21518/2079-701X-2016-07-78-81.@@ Руженцова Т. А., Плоскирева А. А., Горелов А. В. Острая диарея бактериальной этиологии: дифференциальная диагностика и лечение. Медицинский совет. 2016; 7: 78-81. doi: 10.21518/2079-701X-2016-07-78-81.</mixed-citation><mixed-citation xml:lang="en">Ruzhentsova T. A., Ploskireva A. A., Gorelov A. V. Acute diarrhea of bacterial etiology: differential diagnosis and treatment. Meditsinskiy Sovet. 2016; 7: 78-81. (In Russ.) doi: 10.21518/2079-701X-2016-07-78-81.@@ Руженцова Т. А., Плоскирева А. А., Горелов А. В. Острая диарея бактериальной этиологии: дифференциальная диагностика и лечение. Медицинский совет. 2016; 7: 78-81. doi: 10.21518/2079-701X-2016-07-78-81.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Sharif-Askari N.S., Sharif-Askari F.S., Alabed M. et al. Airways Expression of SARS-CoV-2 Receptor, ACE2, and TMPRSS2 Is Lower in Children Than Adults and Increases with Smoking and COPD. Mol Ther Methods Clin Dev. 2020; 18: 1-6. doi: 10.1016/j.omtm.2020.05.013.</mixed-citation><mixed-citation xml:lang="en">Sharif-Askari N.S., Sharif-Askari F.S., Alabed M. et al. Airways Expression of SARS-CoV-2 Receptor, ACE2, and TMPRSS2 Is Lower in Children Than Adults and Increases with Smoking and COPD. Mol Ther Methods Clin Dev. 2020; 18: 1-6. doi: 10.1016/j.omtm.2020.05.013.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Alabsi S., Dhole A., HozayenS. et al. Angiotensin-Converting Enzyme 2 Expression and Severity of SARS-CoV-2 Infection. Microorganisms. 2023; 11(3): 612. doi: 10.3390/microorganisms11030612.</mixed-citation><mixed-citation xml:lang="en">Alabsi S., Dhole A., HozayenS. et al. Angiotensin-Converting Enzyme 2 Expression and Severity of SARS-CoV-2 Infection. Microorganisms. 2023; 11(3): 612. doi: 10.3390/microorganisms11030612.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Jia H. P., Look D. C., Shi L. et al. ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway Epithelia. Journal of Virology. 2005; 79(23): 14614-14621. doi: 10.1128/jvi.79.23.14614-14621.2005.</mixed-citation><mixed-citation xml:lang="en">Jia H. P., Look D. C., Shi L. et al. ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway Epithelia. Journal of Virology. 2005; 79(23): 14614-14621. doi: 10.1128/jvi.79.23.14614-14621.2005.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Sposato B., Scalese M. Why do children seem to be more protected against COVID-19? A hypothesis. Med Hypotheses. 2020; 143: 110151. doi: 10.1016/j.mehy.2020.110151.</mixed-citation><mixed-citation xml:lang="en">Sposato B., Scalese M. Why do children seem to be more protected against COVID-19? A hypothesis. Med Hypotheses. 2020; 143: 110151. doi: 10.1016/j.mehy.2020.110151.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Schurink B., Roos E., Vos W. et al. ACE2 Protein Expression During Childhood, Adolescence, and Early Adulthood. Pediatr Dev Pathol. 2022; 25(4): 404-408. doi: 10.1177/10935266221075312.</mixed-citation><mixed-citation xml:lang="en">Schurink B., Roos E., Vos W. et al. ACE2 Protein Expression During Childhood, Adolescence, and Early Adulthood. Pediatr Dev Pathol. 2022; 25(4): 404-408. doi: 10.1177/10935266221075312.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Collier F., ChauC., Mansell T. et al. Innate Immune Activation and Circulating Inflammatory Markers in Preschool Children. Front Immunol. 2022; 12: 830049. doi: 10.3389/fimmu.2021.830049.</mixed-citation><mixed-citation xml:lang="en">Collier F., ChauC., Mansell T. et al. Innate Immune Activation and Circulating Inflammatory Markers in Preschool Children. Front Immunol. 2022; 12: 830049. doi: 10.3389/fimmu.2021.830049.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Pierce C. A., Sy S., Galen B. et al. Natural Mucosal Barriers and COVID-19 in Children. MedRxiv. 2021: 2021.02.12.21251310. doi: 10.1101/2021.02.12.21251310.</mixed-citation><mixed-citation xml:lang="en">Pierce C. A., Sy S., Galen B. et al. Natural Mucosal Barriers and COVID-19 in Children. MedRxiv. 2021: 2021.02.12.21251310. doi: 10.1101/2021.02.12.21251310.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Furman E. G., Khuzina E. A., Repetskaya M. N. Bronchial Asthma in Children Amidst the Novel Coronavirus Infection. Doctor.Ru. 2020; 19(10): 42-47. (In Russ.) doi: 10.31550/1727-2378-2020-19-10-42-47.@@ Фурман Е. Г., Хузина Е. А., Репецкая М. Н. Бронхиальная астма у детей в условиях новой коронавирусной инфекции. Доктор.Ру. 2020; 19(10): 42-47. doi: 10.31550/1727-2378-2020-19-10-42-47.</mixed-citation><mixed-citation xml:lang="en">Furman E. G., Khuzina E. A., Repetskaya M. N. Bronchial Asthma in Children Amidst the Novel Coronavirus Infection. Doctor.Ru. 2020; 19(10): 42-47. (In Russ.) doi: 10.31550/1727-2378-2020-19-10-42-47.@@ Фурман Е. Г., Хузина Е. А., Репецкая М. Н. Бронхиальная астма у детей в условиях новой коронавирусной инфекции. Доктор.Ру. 2020; 19(10): 42-47. doi: 10.31550/1727-2378-2020-19-10-42-47.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Novikova Yu. Yu., Ovsyannikov D. Yu., Glazyrina A. A. et al. Multisystem inflammatory syndrome in children associated with COVID-19: results of a multicenter study. Pediatria n. a. G. N. Speransky. 2021; 100 (6): 23-31. (In Russ.) doi: 10.24110/0031-403X-2021-100-6-23-31.@@ Новикова Ю. Ю., Овсянников Д. Ю., Глазырина А. А. и др. Детский мультисистемный воспалительный синдром, ассоциированный с новой коронавирусной инфекцией COVID-19: результаты многоцентрового исследования. Педиатрия им. Г. Н. Сперанского. 2021; 100 (6): 23-31. doi: 10.24110/0031-403X-2021-100-6-23-31.</mixed-citation><mixed-citation xml:lang="en">Novikova Yu. Yu., Ovsyannikov D. Yu., Glazyrina A. A. et al. Multisystem inflammatory syndrome in children associated with COVID-19: results of a multicenter study. Pediatria n. a. G. N. Speransky. 2021; 100 (6): 23-31. (In Russ.) doi: 10.24110/0031-403X-2021-100-6-23-31.@@ Новикова Ю. Ю., Овсянников Д. Ю., Глазырина А. А. и др. Детский мультисистемный воспалительный синдром, ассоциированный с новой коронавирусной инфекцией COVID-19: результаты многоцентрового исследования. Педиатрия им. Г. Н. Сперанского. 2021; 100 (6): 23-31. doi: 10.24110/0031-403X-2021-100-6-23-31.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Rostad C. A., Chahroudi A., Mantus G. et al, Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C). Pediatrics. 2020; 146(6): e2020018242. doi: 10.1542/peds.2020-018242.</mixed-citation><mixed-citation xml:lang="en">Rostad C. A., Chahroudi A., Mantus G. et al, Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C). Pediatrics. 2020; 146(6): e2020018242. doi: 10.1542/peds.2020-018242.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Pfeifer J., Thurner B., Kessel C. et al. Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: a multicentre, retrospective, cohort study. Lancet Rheumatol. 2022; 4(5): e329-e337. doi: 10.1016/S2665-9913(22)00064-9.</mixed-citation><mixed-citation xml:lang="en">Pfeifer J., Thurner B., Kessel C. et al. Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: a multicentre, retrospective, cohort study. Lancet Rheumatol. 2022; 4(5): e329-e337. doi: 10.1016/S2665-9913(22)00064-9.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Jain E., Donowitz J. R., Aarons E. et al. Multisystem Inflammatory Syndrome in Children after SARS-CoV-2 Vaccination. Emerg Infect Dis. 2022; 28(5): 990-993. doi: 10.3201/eid2805.212418.</mixed-citation><mixed-citation xml:lang="en">Jain E., Donowitz J. R., Aarons E. et al. Multisystem Inflammatory Syndrome in Children after SARS-CoV-2 Vaccination. Emerg Infect Dis. 2022; 28(5): 990-993. doi: 10.3201/eid2805.212418.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Yousaf A. R., Cortese M. M., Taylor A. W. et al. Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation. Lancet Child Adolesc Health. 2022; 6(5): 303-312. doi: 10.1016/S2352-4642(22)00028-1.</mixed-citation><mixed-citation xml:lang="en">Yousaf A. R., Cortese M. M., Taylor A. W. et al. Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation. Lancet Child Adolesc Health. 2022; 6(5): 303-312. doi: 10.1016/S2352-4642(22)00028-1.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Filippatos F., Tatsi E.-B., Michos A. Innate Immune Activation and Circulating Inflammatory Markers in Preschool Children.Int J Mol Sci. 2023; 24(6): 5711. doi: 10.3390/ijms24065711.</mixed-citation><mixed-citation xml:lang="en">Filippatos F., Tatsi E.-B., Michos A. Innate Immune Activation and Circulating Inflammatory Markers in Preschool Children.Int J Mol Sci. 2023; 24(6): 5711. doi: 10.3390/ijms24065711.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
